Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-8273a + nivolumab
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DS-8273a + nivolumab is a combination of two investigational monoclonal antibodies being studied for the treatment of advanced cancers, particularly unresectable Stage III or IV melanoma. DS-8273a is an agonistic anti-death receptor 5 (DR5, also known as TRAIL-R2) monoclonal antibody that selectively targets and eliminates myeloid-derived suppressor cells (MDSCs), which are immunosuppressive cells in the tumor microenvironment. By depleting MDSCs, DS-8273a may enhance anti-tumor immune responses. Nivolumab is a well-established anti-PD1 immune checkpoint inhibitor that blocks programmed death receptor 1 (PD1) on T-cells to promote immune-mediated tumor cell killing. The combination aims to improve cancer immunotherapy efficacy by both reducing immunosuppression and enhancing T-cell activity[1][2][4].
- Brand names
- nivolumab (Opdivo)
- Other names
- TRAIL D5 antibodyTRAIL-R2 agonistic antibodyTRAIL-R-2 agonistic antibodyTRAIL-R 2 agonistic antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TNFRSF10B (DR5)
Beyond the preview
Go deeper on DS-8273a + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-8273a + nivolumab.